The EIF2AK3 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the EIF2AK3 gene (encoding PERK) in a human non-small cell lung adenocarcinoma model. This loss-of-function pool eliminates functional PERK kinase activity, providing a versatile tool for dissecting PERK-dependent signaling without clonal selection artifacts. The knockout is introduced via CRISPR/Cas9-mediated gene disruption, generating a heterogeneous population that reliably models PERK deficiency for biochemical and functional assays. Researchers can employ these polyclonal knockout cells to investigate endogenous ER stress responses and downstream pathway activation in a genetically defined lung cancer background.
The host cell line, NCI-H1975, is an epithelial human lung adenocarcinoma line harboring activating EGFR mutations (L858R and T790M). This genetic profile renders the cells dependent on EGFR-driven survival signaling and resistant to first-generation tyrosine kinase inhibitors, making them a key model for acquired drug resistance. The epithelial origin and adherent growth characteristics facilitate standard culture, transfection, and high-content imaging workflows. Because NCI-H1975 cells exhibit elevated basal ER stress and unfolded protein response (UPR) activity linked to oncogenic signaling, they serve as a pathophysiologically relevant system for evaluating PERK function in cancer biology.
PERK is a serine/threonine kinase that functions as a central ER stress sensor. Under basal conditions, it is kept inactive through association with BiP/GRP78; upon accumulation of misfolded proteins, BiP dissociates, triggering PERK oligomerization, autophosphorylation, and activation. Active PERK phosphorylates eIF2??, attenuating global translation while selectively enhancing ATF4 translation. ATF4 transcriptionally upregulates genes involved in amino acid metabolism, redox balance, and apoptosis, including CHOP (DDIT3) and GADD34 (PPP1R15A). Additional interacting factors such as P58IPK (DNAJC3), NRF2, and TXNIP modulate PERK output, linking it to antioxidant responses and cell death decisions. Pharmacological inducers like tunicamycin (N-linked glycosylation inhibitor) and thapsigargin (SERCA inhibitor) are classic tools to experimentally activate this pathway.
In the NCI-H1975 background, PERK signaling intersects with oncogenic EGFR pathways. EGFR mutations can upregulate UPR components, and PERK-dependent translational control may influence apoptosis sensitivity, metabolic reprogramming, and autophagy, all of which contribute to therapeutic resistance. Disrupting EIF2AK3 in this context allows investigators to uncouple PERK-mediated stress adaptation from other UPR branches (IRE1??, ATF6), clarifying its specific contribution to cell survival under drug challenge or microenvironmental stress. This model is thus uniquely suited to identify vulnerabilities that can be exploited by combination therapies targeting ER stress machinery in EGFR-mutant lung cancers.
Typical applications include mechanistic studies of UPR-dependent drug resistance, apoptosis regulation, and metabolic adaptation. Researchers can quantify PERK pathway activation by Western blotting for total and phosphorylated PERK, phospho-eIF2??, ATF4, and CHOP; qPCR analysis of UPR target genes (e.g., CHOP, GADD34); and cell viability assays (MTT or CellTiter-Glo) following treatment with tunicamycin or thapsigargin. Flow cytometric annexin V staining enables apoptosis profiling under ER stress. These polyclonal knockout cells also support phospho-signaling array analysis and co-culture experiments to explore tumor?Cstroma interactions. For further information or to discuss custom applications, contact Ascent Research.
